Charles Farthing

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

Richard A. Koup, Jeffrey T. Safrit, Yaming Cao et al. · Journal of Virology · 1994 · 2.5K citations · Full text

Immunology, Immunotherapy, Human Retrovirus +18

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina et al. · The Lancet · 2007 · 480 citations

Treatment And Prevention, Week 48, Antiviral Drug Development +9

Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

Edwin DeJesus, Daniel Berger, Martin Markowitz et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 268 citations

PREVALENCE OF ANTIBODY TO HUMAN T-LYMPHOTROPIC VIRUS TYPE III IN AIDS AND AIDS-RISK PATIENTS IN BRITAIN

R. Cheingsong‐Popov, Richard Weiss, Angus Dalgleish et al. · The Lancet · 1984 · 228 citations

Primary Immunodeficiency, Human Retrovirus, Immunology +6

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

D. William Cameron, Anthony J. Japour, Yi Xu et al. · AIDS · 1999 · 198 citations